Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Preetesh Jain

Showing results (151-160 of 176) with videos related to

Pageof 18
Sort By:
Cancer|June 1, 2016
Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomesGevorg N Tamamyan, Hagop M Kantarjian, Jing Ning, et al.
American Journal of Hematology|November 12, 2020
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomesKoji Sasaki, Elias J Jabbour, Farhad Ravandi, et al.
Frontiers in Oncology|September 26, 2024
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organsGohar S Manzar, Elaine E Cha, Kelsey L Corrigan, et al.
Cancer|July 26, 2017
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patientsPreetesh Jain, Hagop M Kantarjian, Ahmad Ghorab, et al.
Blood Cancer Journal|July 2, 2026
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphomaKaran L Chohan, Eduardo Edelman Saul, R Eric Davis, et al.
Leukemia|September 28, 2019
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphomaMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
Cancer|June 14, 2017
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimensRashmi Kanagal-Shamanna, Preetesh Jain, Koichi Takahashi, et al.
American Journal of Hematology|October 20, 2017
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphomaYasmin Abaza, Hagop M Kantarjian, Stefan Faderl, et al.
Blood|July 23, 2025
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphomaWei Wang, Qingsong Cai, Yang Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2021
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell LymphomaPreetesh Jain, Shuangtao Zhao, Hun Ju Lee, et al.
Pageof 18

Showing results (151-160 of 176) with videos related to

Sort By:
Pageof 18
Cancer|June 1, 2016
Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomesGevorg N Tamamyan, Hagop M Kantarjian, Jing Ning, et al.
American Journal of Hematology|November 12, 2020
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomesKoji Sasaki, Elias J Jabbour, Farhad Ravandi, et al.
Frontiers in Oncology|September 26, 2024
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organsGohar S Manzar, Elaine E Cha, Kelsey L Corrigan, et al.
Cancer|July 26, 2017
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patientsPreetesh Jain, Hagop M Kantarjian, Ahmad Ghorab, et al.
Blood Cancer Journal|July 2, 2026
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphomaKaran L Chohan, Eduardo Edelman Saul, R Eric Davis, et al.
Leukemia|September 28, 2019
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphomaMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
Cancer|June 14, 2017
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimensRashmi Kanagal-Shamanna, Preetesh Jain, Koichi Takahashi, et al.
American Journal of Hematology|October 20, 2017
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphomaYasmin Abaza, Hagop M Kantarjian, Stefan Faderl, et al.
Blood|July 23, 2025
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphomaWei Wang, Qingsong Cai, Yang Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2021
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell LymphomaPreetesh Jain, Shuangtao Zhao, Hun Ju Lee, et al.
Pageof 18